A non steroidal anti-inflammatory drug NSAID, Mefenamic acid is predominantly used for treating mild to moderate dysmenorrhea or menstrual pain for a short term, for not more than a week. It may also be used for treating other symptoms at the discretion of the doctor. Mefenamic acid helps to reduce inflammation and thereby pain by blocking the production of some of the body chemicals that cause inflammation, pain, tenderness, stiffness, swelling and increased temperature.
Mefenamic acid blocks the body from producing prostaglandins that are linked to inflammation, thus treating the symptoms of pain and inflammation. In muscles and joints, Mefenamic acid helps to improve movement by reducing inflammation, although it may take a few weeks to relieve pain after the first few doses. This medicine is normally prescribed at the lowest possible dose for the shortest period of time to reduce chances of any side-effects. However, Mefenamic acid should not be taken if the patient exhibits the following:
Before using Mefenamic acid, a woman must check the following:
Using Mefenamic acid
There are some medicines which could interact with Mefenamic acid and the healthcare provider has to be informed if any one of the following is taken:
This acid has to be used with great caution as it could cause dizziness or drowsiness. This can get worse if you take it with alcohol or certain medicines. As Mefenamic acid may interfere with certain lab tests, be sure that the doctor or lab technologist knows that Mefenamic acid is being taken - especially in case of blood cell counts, blood pressure, kidney function tests.
Enter your health or medical queries in our Artificial Intelligence powered Application here. Our Natural Language Navigational engine knows that words form only the outer superficial layer. The real meaning of the words are deduced from the collection of words, their proximity to each other and the context.
Diseases, Symptoms, Tests and Treatment arranged in alphabetical order:
Bibliography / Reference
Collection of Pages - Last revised Date: July 30, 2021